Pharmacoepidemiology and drug safetyHumansGlucagon-Like PeptidesDiabetes MellitusType 2Female
Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.
Kasper Bonnesen, Uffe Heide-Jørgensen, Diana H Christensen, Timothy L Lash, Lars Pedersen, Reimar W Thomsen, Anthony A Matthews, Morten Schmidt
Published: 202510.1002/pds.70276
Abstract
OBJECTIVE: Randomized clinical trials show that subcutaneous semaglutide is modestly superior to dulaglutide in reducing HbA1c and body weight, but no trial has compared their effectiveness on hard cardiovascular outcomes. This study aimed to examine…
Preview only. Read the full abstract at the source